Actinium Pharmaceuticals (NYSE:ATNM) Stock Price Up 1.9% – Here’s What Happened

Shares of Actinium Pharmaceuticals, Inc. (NYSE:ATNM) traded up 1.9% on Tuesday . The company traded as high as $0.9201 and last traded at $0.90. Approximately 50,584 shares traded hands during mid-day trading, a decline of 65% from the average daily volume of 145,028 shares. The stock had previously closed at $0.8830.

Analysts Set New Price Targets

Separately, Stephens reiterated an “overweight” rating and set a $5.00 target price on shares of Actinium Pharmaceuticals in a report on Tuesday, March 31st. One research analyst has rated the stock with a Buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $5.00.

Actinium Pharmaceuticals Stock Performance

The company has a 50 day moving average of $1.05 and a 200 day moving average of $1.14. The stock has a market capitalization of $27.96 million, a price-to-earnings ratio of -0.64 and a beta of -0.02.

Institutional Investors Weigh In On Actinium Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of ATNM. AM Investment Strategies LLC purchased a new position in Actinium Pharmaceuticals in the fourth quarter valued at $40,000. Qube Research & Technologies Ltd purchased a new stake in Actinium Pharmaceuticals during the 2nd quarter worth about $70,000. Bailard Inc. acquired a new position in shares of Actinium Pharmaceuticals during the 4th quarter worth about $79,000. Squarepoint Ops LLC purchased a new position in shares of Actinium Pharmaceuticals in the 4th quarter valued at about $89,000. Finally, Goldman Sachs Group Inc. purchased a new position in shares of Actinium Pharmaceuticals in the 4th quarter valued at about $96,000. 27.50% of the stock is currently owned by institutional investors and hedge funds.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on the development of targeted radiopharmaceutical therapies for patients with hematologic malignancies. The company’s proprietary technology platform combines monoclonal antibodies with radioisotopes to deliver highly potent, cell‐killing radiation directly to cancer cells while sparing healthy tissues. Actinium’s lead product candidate, Iomab‐B, is being evaluated as a conditioning regimen for older patients with acute myeloid leukemia (AML) who are ineligible for standard bone marrow transplants.

In addition to Iomab‐B, Actinium’s pipeline includes Actimab‐A, an anti‐CD33 antibody labeled with the radioisotope bismuth‐213 for the treatment of relapsed or refractory AML.